Siemens completes energy-saving modernization at Berlin State Library

Anthony Casciano President and CEO Siemens Financial Services
Anthony Casciano President and CEO - Siemens Financial Services
0Comments

Siemens has completed a technical modernization of the Staatsbibliothek zu Berlin, aiming to reduce the library’s energy use and CO₂ emissions. The project is intended to help protect cultural assets housed in the facility.

According to Siemens, the upgrades have resulted in halving the building’s energy consumption. The company reports that these changes are expected to contribute significantly to climate protection goals by reducing greenhouse gas output from one of Berlin’s major public institutions.

“Siemens has technically modernized the Staatsbibliothek zu Berlin (Berlin State Library) to slash the facility’s energy consumption, lower its CO₂ emissions and better protect valuable cultural assets.”

The modernization aligns with ongoing efforts across Germany and Europe to make public buildings more energy efficient. The Staatsbibliothek zu Berlin is among several heritage sites investing in new technologies for sustainability and preservation purposes.



Related

Paul Hudson Chief Executive Officer Sanofi SA

Acoziborole receives key EU panel backing as single-dose treatment for sleeping sickness

Acoziborole Winthrop, a new oral treatment for sleeping sickness developed by the Drugs for Neglected Diseases initiative (DNDi) and Sanofi, has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for…

Martin Lundstedt President and CEO at Volvo Group North America LLC Volvo Group North America LLC

Volvo announces updated share and vote count after series conversion

The number of votes in AB Volvo has changed following the conversion of 2,000,619 Series A shares into an equal number of Series B shares.

Paul Hudson Chief Executive Officer Sanofi SA

Sanofi and Regeneron’s Dupixent recommended for EU approval in young children with chronic urticaria

Sanofi and Regeneron have announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Dupixent (dupilumab) for children aged two to 11 years with…

Trending

The Weekly Newsletter

Sign-up for the Weekly Newsletter from EU Business Daily.